BEGIN:VCALENDAR
VERSION:2.0
PRODID:default
X-WR-TIMEZONE:Europe/Berlin
BEGIN:VTIMEZONE
TZID:Europe/Berlin
X-LIC-LOCATION:Europe/Berlin
BEGIN:DAYLIGHT
TZNAME:CEST
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:DAYLIGHT
TZNAME:CEST
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZNAME:CET
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
DTSTART:20211031T010000
END:STANDARD
BEGIN:STANDARD
TZNAME:CET
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
DTSTART:20221030T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
UID:59381c24cfaf51e101a5b4ee13a92dc1
DTSTART;TZID=Europe/Berlin:20220321T150000
SEQUENCE:0
TRANSP:OPAQUE
URL:https://www.mdc-berlin.de/immunology/seminar/kariko
LOCATION:Robert-Rössle Straße 10 Axon 1 + 2\,13125 Berlin\,Germany
SUMMARY:Katalin Karikó - My long winding road to develop mRNA for therapy
CLASS:PUBLIC
DESCRIPTION:IMMUNOLOGY & INFLAMMATION (I&I) -  SEMINAR SERIES\n\nMessenger
  RNA was discovered in 1961 and it took 60 years until the\nfirst mRNA bec
 ame FDA-approved product in the form of COVID-19 mRNA\nvaccine. During tho
 se years a lot of progress has been made by\nhundreds of scientists. It wa
 s 1978 when the first time isolated mRNA\ndelivered into mammalian cells p
 roduced the encoded protein. In vitro\ntranscription introduced in 1984 ma
 de it possible to generate any\ndesired mRNA from the encoding plasmid usi
 ng phage RNA polymerases. In\nthe early 90s mRNA was used for therapy as w
 ell as vaccine against\ninfectious diseases and cancer. Inflammatory natur
 e of the mRNA\nlimited its in vivo use. Replacing uridine with pseudouridi
 ne made the\nmRNA non-immunogenic and highly translatable. Delivery of the
  lipid\nnanoparticle-formulated nucleoside-modified mRNA encoding viral\na
 ntigens became a platform for effective vaccine. Labile nature of the\nmRN
 A is ideal for transient production of the viral antigen\, to\ngenerate ef
 fective antibody and cellular immune response.\n
X-ALT-DESC;FMTTYPE=text/html:<h3>Immunology &amp\; Inflammation (I&amp\;I) 
 -&nbsp\; Seminar Series</h3>\n\n<p><span><span><span><span lang=\"EN-GB\">
 <span><span>Messenger RNA was discovered in 1961 and it took 60 years unti
 l the first mRNA became FDA-approved product in the form of COVID-19 mRNA 
 vaccine. During those years a lot of progress has been made by hundreds of
  scientists. It was 1978 when the first time isolated mRNA delivered into 
 mammalian cells produced the encoded protein. In vitro transcription intro
 duced in 1984 made it possible to generate any desired mRNA from the encod
 ing plasmid using phage RNA polymerases. In the early 90s mRNA was used fo
 r therapy as well as vaccine against infectious diseases and cancer. Infla
 mmatory nature of the mRNA limited its in vivo use. Replacing uridine with
  pseudouridine made the mRNA non-immunogenic and highly translatable. Deli
 very of the lipid nanoparticle-formulated nucleoside-modified mRNA encodin
 g viral antigens became a platform for effective vaccine. Labile nature of
  the mRNA is ideal for transient production of the viral antigen\, to gene
 rate effective antibody and cellular immune response.</span></span></span>
 </span></span></span></p>
DTSTAMP:20240529T172231Z
END:VEVENT
END:VCALENDAR